1887

Abstract

Genetic immunization using viral vectors provides an effective means to elicit antigen-specific cellular immune responses. Several viral vectors have proven efficacious in inducing immune responses after direct injection . Among them, recombinant, self-inactivating lentiviral vectors are very attractive delivery systems, as they are able to efficiently transduce into and express foreign genes in a wide variety of mammalian cells. A self-inactivating lentiviral vector was evaluated for the delivery of human immunodeficiency virus 1 (HIV-1) envelope sequences in mice in order to elicit specific immune responses. With this aim, BALB/c mice were immunized with a single injection of self-inactivating lentiviral vectors carrying either the full-length HIV-1 Rev/Env (TY2-IIIBEnv) or the codon-optimized HIV-1 gp120 (TY2-JREnv) coding sequence. Both vectors were able to elicit specific cellular responses efficiently, as measured by gamma interferon ELISPOT and chromium-release assays, upon stimulation of splenocytes from BALB/c immunized mice. However, only the TY2-JREnv-immunized mice were able to elicit specific humoral responses, measured as anti-gp120 antibody production. These data provide the first evidence that a single, direct, administration of a lentiviral vector encoding a viral gene might represent a useful strategy for vaccine development.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81706-0
2006-06-01
2019-12-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/6/1625.html?itemId=/content/journal/jgv/10.1099/vir.0.81706-0&mimeType=html&fmt=ahah

References

  1. Alexander-Miller, M. A., Parker, K. C., Tsukui, T., Pendleton, C. D., Coligan, J. E. & Berzofsky, J. A. ( 1996; ). Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int Immunol 8, 641–649.[CrossRef]
    [Google Scholar]
  2. Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B. & Stott, E. J. ( 1995; ). Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345, 1342–1344.[CrossRef]
    [Google Scholar]
  3. Amara, R. R., Villinger, F., Altman, J. D. & 19 other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  4. André, S., Seed, B., Eberle, J., Schraut, W., Bültmann, A. & Haas, J. ( 1998; ). Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72, 1497–1503.
    [Google Scholar]
  5. Anson, D. S. ( 2004; ). The use of retroviral vectors for gene therapy – what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2, 9.[CrossRef]
    [Google Scholar]
  6. Baba, T. W., Liska, V., Khimani, A. H. & 8 other authors ( 1999; ). Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5, 194–203.[CrossRef]
    [Google Scholar]
  7. Barouch, D. H., Santra, S., Schmitz, J. E. & 26 other authors ( 2000; ). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492.[CrossRef]
    [Google Scholar]
  8. Barouch, D. H., Letvin, N. L. & Seder, R. A. ( 2004; ). The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202, 266–274.[CrossRef]
    [Google Scholar]
  9. Barquinero, J., Eixarch, H. & Pérez-Melgosa, M. ( 2004; ). Retroviral vectors: new applications for an old tool. Gene Ther 11, S3–S9.[CrossRef]
    [Google Scholar]
  10. Berzofsky, J. A., Ahlers, J. D., Janik, J., Morris, J., Oh, S., Terabe, M. & Belyakov, I. M. ( 2004; ). Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114, 450–462.[CrossRef]
    [Google Scholar]
  11. Chang, L.-J. & He, J. ( 2001; ). Retroviral vectors for gene therapy of AIDS and cancer. Curr Opin Mol Ther 3, 468–475.
    [Google Scholar]
  12. Chang, L.-J., Urlacher, V., Iwakuma, T., Cui, Y. & Zucali, J. ( 1999; ). Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther 6, 715–728.[CrossRef]
    [Google Scholar]
  13. Chinnasamy, N., Treisman, J. S., Oaks, M. K., Hanson, J. P., Jr & Chinnasamy, D. ( 2005; ). Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination. Gene Ther 12, 259–271.[CrossRef]
    [Google Scholar]
  14. Cockrell, A. S. & Kafri, T. ( 2003; ). HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go. Curr HIV Res 1, 419–439.[CrossRef]
    [Google Scholar]
  15. Connolly, J. B. ( 2002; ). Lentiviruses in gene therapy clinical research. Gene Ther 9, 1730–1734.[CrossRef]
    [Google Scholar]
  16. Couzin, J. & Kaiser, J. ( 2005; ). As Gelsinger case ends, gene therapy suffers another blow. Science 307, 1028.
    [Google Scholar]
  17. Crameri, A., Whitehorn, E. A., Tate, E. & Stemmer, W. P. C. ( 1996; ). Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 14, 315–319.[CrossRef]
    [Google Scholar]
  18. Cranage, M. P., Whatmore, A. M., Sharpe, S. A. & 7 other authors ( 1997; ). Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 229, 143–154.[CrossRef]
    [Google Scholar]
  19. Cui, Y., Iwakuma, T. & Chang, L. J. ( 1999; ). Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 73, 6171–6176.
    [Google Scholar]
  20. Esslinger, C., Chapatte, L., Finke, D., Miconnet, I., Guillaume, P., Lévy, F. & MacDonald, H. R. ( 2003; ). In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses. J Clin Invest 111, 1673–1681.[CrossRef]
    [Google Scholar]
  21. Firat, H., Zennou, V., Garcia-Pons, F., Ginhoux, F., Cochet, M., Danos, O., Lemonnier, F. A., Langlade-Demoyen, P. & Charneau, P. ( 2002; ). Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 4, 38–45.[CrossRef]
    [Google Scholar]
  22. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S. & Tartaglia, J. ( 2004; ). Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3, S75–S88.[CrossRef]
    [Google Scholar]
  23. Gao, F., Li, Y., Decker, J. M. & 11 other authors ( 2003; ). Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Res Hum Retroviruses 19, 817–823.[CrossRef]
    [Google Scholar]
  24. Gómez, C. E., Abaitua, F., Rodríguez, D. & Esteban, M. ( 2004; ). Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ. Virus Res 105, 11–22.[CrossRef]
    [Google Scholar]
  25. Goulder, P. J., Rowland-Jones, S. L., McMichael, A. J. & Walker, B. D. ( 1999; ). Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 13 (Suppl. A), S121–S136.
    [Google Scholar]
  26. Grignani, F., Kinsella, T., Mencarelli, A. & 7 other authors ( 1998; ). High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res 58, 14–19.
    [Google Scholar]
  27. Haas, J., Park, E.-C. & Seed, B. ( 1996; ). Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 6, 315–324.[CrossRef]
    [Google Scholar]
  28. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M. & 32 other authors ( 2003; ). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419.[CrossRef]
    [Google Scholar]
  29. He, Y., Zhang, J., Mi, Z., Robbins, P. & Falo, L. D., Jr ( 2005; ). Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174, 3808–3817.[CrossRef]
    [Google Scholar]
  30. Heeney, J. L. ( 2004; ). Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 3, S53–S64.[CrossRef]
    [Google Scholar]
  31. Heeney, J. L., Holterman, L., ten Haaft, P., Dubbes, R., Koornstra, W., Teeuwsen, V., Bourquin, P., Norley, S. & Niphuis, H. ( 1994; ). Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge. AIDS Res Hum Retroviruses 10, S117–S121.
    [Google Scholar]
  32. Im, E. J. & Hanke, T. ( 2004; ). MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3, S89–S97.[CrossRef]
    [Google Scholar]
  33. Irwin, M. J., Laube, L. S., Lee, V., Austin, M., Chada, S., Anderson, C.-G., Townsend, K., Jolly, D. J. & Warner, J. F. ( 1994; ). Direct injection of a recombinant retroviral vector induces human immunodeficency virus-specific immune responses in mice and nonhuman primates. J Virol 68, 5036–5044.
    [Google Scholar]
  34. Iwakuma, T., Cui, Y. & Chang, L.-J. ( 1999; ). Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 261, 120–132.[CrossRef]
    [Google Scholar]
  35. Jaffray, A., Shephard, E., van Harmelen, J., Williamson, C., Williamson, A. L. & Rybicki, E. P. ( 2004; ). Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice. J Gen Virol 85, 409–413.[CrossRef]
    [Google Scholar]
  36. Johnson, R. P. & Desrosiers, R. C. ( 1998; ). Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 10, 436–443.[CrossRef]
    [Google Scholar]
  37. Johnson, P. R., Schnepp, B. C., Connell, M. J. & 8 other authors ( 2005; ). Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 79, 955–965.[CrossRef]
    [Google Scholar]
  38. Kamantigue, E., Edwards, W., III, Chada, S., Brumm, D., Austin, M., Irwin, M., Mento, S., Kowal, K. & Sajjadi, N. ( 1996; ). Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther 3, 128–136.
    [Google Scholar]
  39. Kaul, R., Rowland-Jones, S. L., Kimani, J. & 12 other authors ( 2001; ). New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 79, 3–13.[CrossRef]
    [Google Scholar]
  40. Kim, C. H., Oh, Y. & Lee, T. H. ( 1997; ). Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene 199, 293–301.[CrossRef]
    [Google Scholar]
  41. Koya, R. C., Kasahara, N., Favaro, P. M. B., Lau, R., Ta, H. Q., Weber, J. S. & Stripecke, R. ( 2003; ). Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 26, 451–460.[CrossRef]
    [Google Scholar]
  42. Kumar, A. & Narayan, O. ( 2001; ). Immunization for long-term protection against AIDS using the macaque model. Virology 285, 1–5.[CrossRef]
    [Google Scholar]
  43. Kung, S. K. P., Bonifacino, A., Metzger, M. E., Ringpis, G.-E., Donahue, R. E. & Chen, I. S. Y. ( 2005; ). Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum Gene Ther 16, 527–532.[CrossRef]
    [Google Scholar]
  44. Laube, L. S., Burrascano, M., Dejesus, C. E. & 11 other authors ( 1994; ). Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther 5, 853–862.[CrossRef]
    [Google Scholar]
  45. Letvin, N. L. ( 1998; ). What immunity can protect against HIV infection? J Clin Invest 102, 1643–1644.[CrossRef]
    [Google Scholar]
  46. Letvin, N. L. ( 2002; ). Strategies for an HIV vaccine. J Clin Invest 110, 15–27.[CrossRef]
    [Google Scholar]
  47. Leung, L., Srivastava, I. K., Kan, E., Legg, H., Sun, Y., Greer, C., Montefiori, D. C., zur Megede, J. & Barnett, S. W. ( 2004; ). Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18, 991–1001.[CrossRef]
    [Google Scholar]
  48. Lever, A. M., Strappe, P. M. & Zhao, J. ( 2004; ). Lentiviral vectors. J Biomed Sci 11, 439–449.[CrossRef]
    [Google Scholar]
  49. Liu, M., Acres, B., Balloul, J.-M., Bizouarne, N., Paul, S., Slos, P. & Squiban, P. ( 2004; ). Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 101, 14567–14571.[CrossRef]
    [Google Scholar]
  50. Mäkitalo, B., Lundholm, P., Hinkula, J. & 9 other authors ( 2004; ). Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 85, 2407–2419.[CrossRef]
    [Google Scholar]
  51. Manilla, P., Rebello, T., Afable, C. & 10 other authors ( 2005; ). Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16, 17–25.[CrossRef]
    [Google Scholar]
  52. McMichael, A. & Hanke, T. ( 2002; ). The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2, 283–291.[CrossRef]
    [Google Scholar]
  53. Morizono, K., Xie, Y., Ringpis, G.-E., Johnson, M., Nassanian, H., Lee, B., Wu, L. & Chen, I. S. Y. ( 2005; ). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11, 346–352.[CrossRef]
    [Google Scholar]
  54. Nagata, T., Uchijima, M., Yoshida, A., Kawashima, M. & Koide, Y. ( 1999; ). Codon optimization effect on translational efficiency of DNA vaccine in mammalian cells: analysis of plasmid DNA encoding a CTL epitope derived from microorganisms. Biochem Biophys Res Commun 261, 445–451.[CrossRef]
    [Google Scholar]
  55. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & Trono, D. ( 1996; ). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267.[CrossRef]
    [Google Scholar]
  56. Negri, D. R. M., Baroncelli, S., Catone, S. & 15 other authors ( 2004a; ). Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. J Gen Virol 85, 1191–1201.[CrossRef]
    [Google Scholar]
  57. Negri, D. R. M., Buffa, V., Leone, P. & 7 other authors ( 2004b; ). Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. J Immunol Methods 291, 153–163.[CrossRef]
    [Google Scholar]
  58. Norley, S., Beer, B., Binninger-Schinzel, D., Vogel, T., Siegel, F., Cosma, C., Konig, H., Megede, J. Z. & Kurth, R. ( 1996; ). Simian immunodeficiency virus live and inactivated experimental vaccines. AIDS Res Hum Retroviruses 12, 447–449.[CrossRef]
    [Google Scholar]
  59. Ogg, G. S., Jin, X., Bonhoeffer, S. & 12 other authors ( 1998; ). Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103–2106.[CrossRef]
    [Google Scholar]
  60. Palmowski, M. J., Lopes, L., Ikeda, Y., Salio, M., Cerundolo, V. & Collins, M. K. ( 2004; ). Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 172, 1582–1587.[CrossRef]
    [Google Scholar]
  61. Pinto, A. R., Fitzgerald, J. C., Giles-Davis, W., Gao, G. P., Wilson, J. M. & Ertl, H. C. J. ( 2003; ). Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171, 6774–6779.[CrossRef]
    [Google Scholar]
  62. Pope, M. ( 2003; ). Dendritic cells as a conduit to improve HIV vaccines. Curr Mol Med 3, 229–242.[CrossRef]
    [Google Scholar]
  63. Ramakrishna, L., Anand, K. K., Mohankumar, K. M. & Ranga, U. ( 2004; ). Codon optimization of the Tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78, 9174–9189.[CrossRef]
    [Google Scholar]
  64. Relph, K., Harrington, K. & Pandha, H. ( 2004; ). Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 329, 839–842.[CrossRef]
    [Google Scholar]
  65. Rohrlich, P. S., Cardinaud, S., Lulè, J. & 11 other authors ( 2004; ). Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8+ cytotoxic T cells from human peripheral blood cells. Hum Immunol 65, 514–522.[CrossRef]
    [Google Scholar]
  66. Romano, G., Claudio, P. P., Tonini, T. & Giordano, A. ( 2003; ). Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur J Dermatol 13, 424–429.
    [Google Scholar]
  67. Schmitz, J. E., Kuroda, M. J., Santra, S. & 13 other authors ( 1999; ). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860.[CrossRef]
    [Google Scholar]
  68. Schnell, T., Foley, P., Wirth, M., Munch, J. & Uberla, K. ( 2000; ). Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11, 439–447.[CrossRef]
    [Google Scholar]
  69. Sernicola, L., Corrias, F., Koanga-Mogtomo, M. L. & 10 other authors ( 1999; ). Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 256, 291–302.[CrossRef]
    [Google Scholar]
  70. Shiver, J. W., Fu, T.-M., Chen, L. & 49 other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.[CrossRef]
    [Google Scholar]
  71. Someya, K., Xin, K.-Q., Matsuo, K., Okuda, K., Yamamoto, N. & Honda, M. ( 2004; ). A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J Virol 78, 9842–9853.[CrossRef]
    [Google Scholar]
  72. Tatsis, N. & Ertl, H. C. J. ( 2004; ). Adenoviruses as vaccine vectors. Mol Ther 10, 616–629.[CrossRef]
    [Google Scholar]
  73. Titti, F., Sernicola, L., Geraci, A. & 12 other authors ( 1997; ). Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys. J Gen Virol 78, 2529–2539.
    [Google Scholar]
  74. Truckenmiller, M. E. & Norbury, C. C. ( 2004; ). Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 4, 861–868.[CrossRef]
    [Google Scholar]
  75. Vanniasinkam, T. & Ertl, H. C. J. ( 2005; ). Adenoviral gene delivery for HIV-1 vaccination. Curr Gene Ther 5, 203–212.[CrossRef]
    [Google Scholar]
  76. Vargas, J., Jr, Gusella, G. L., Najfeld, V., Klotman, M. E. & Cara, A. ( 2004; ). Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15, 361–372.[CrossRef]
    [Google Scholar]
  77. Voltan, R. & Robert-Guroff, M. ( 2003; ). Live recombinant vectors for AIDS vaccine development. Curr Mol Med 3, 273–284.[CrossRef]
    [Google Scholar]
  78. Wang, X., Wiley, R. D., Evans, T. G., Bowers, W. J., Federoff, H. J. & Dewhurst, S. ( 2003; ). Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21, 2288–2297.[CrossRef]
    [Google Scholar]
  79. Warner, J. F., Anderson, C. G., Laube, L., Jolly, D. J., Townsend, K., Chada, S. & St Louis, D. ( 1991; ). Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retroviruses 7, 645–655.[CrossRef]
    [Google Scholar]
  80. Weiss, R., Teich, N., Varmus, H. & Coffin, J. ( 1982; ). Molecular biology of tumor viruses. In RNA Tumor Viruses, 2nd edn. Edited by R. Weiss, N. Teich, H. Varmus & J. Coffin. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
  81. Whitney, J. B. & Ruprecht, R. M. ( 2004; ). Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17, 17–26.[CrossRef]
    [Google Scholar]
  82. Woodland, D. L. ( 2004; ). Jump-starting the immune system: prime–boosting comes of age. Trends Immunol 25, 98–104.[CrossRef]
    [Google Scholar]
  83. Young, K. R., Teal, B. E., Brooks, Y., Green, T. D., Bower, J. F. & Ross, T. M. ( 2004; ). Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies. AIDS Res Hum Retroviruses 20, 1259–1268.[CrossRef]
    [Google Scholar]
  84. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A. & Chen, I. S. Y. ( 1990; ). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213–222.[CrossRef]
    [Google Scholar]
  85. Zaiss, A.-K., Son, S. & Chang, L.-J. ( 2002; ). RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 76, 7209–7219.[CrossRef]
    [Google Scholar]
  86. Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J. & Muzyczka, N. ( 1996; ). A “humanized” green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 70, 4646–4654.
    [Google Scholar]
  87. Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L. & Trono, D. ( 1998; ). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72, 9873–9880.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81706-0
Loading
/content/journal/jgv/10.1099/vir.0.81706-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error